An Open Label, Non-randomized Phase 1b Study to Investigate the Safety and Effect of the Oncolytic Virus GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery for Curative-Intent or Palliative Resection
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs GL ONC1 (Primary) ; Eculizumab
- Indications Solid tumours
- Focus Adverse reactions
- 26 Jun 2017 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
- 26 Jun 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 26 Jun 2017 Status changed from recruiting to active, no longer recruiting.